Safety, Tolerability, and Pharmacokinetics of the Anti-Igf-1r Monoclonal Antibody Figitumumab in Patients With Refractory Adrenocortical Carcinoma
Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-009-1083-9
Full Text
Open PDFAbstract
Available in full text
Date
August 2, 2009
Authors
Publisher
Springer Science and Business Media LLC